Table 1.
Clinical characteristics of RCC patients from different cohorts.
| Variable | No. of patients (%) or Median (IQR) |
|||
|---|---|---|---|---|
| Zhongshan cohort (N = 1482) | Zhejiang cohort (N = 433) | Xiamen cohort (N = 126) | TCIA cohort (N = 177) | |
| Age | 58 (50–65) | 56 (48–64) | 56 (45–67) | 59 (50–70) |
| Sex | ||||
| Male | 970 (65.5) | 288 (66.5) | 85 (67.5) | 118 (66.7) |
| Female | 512 (34.5) | 145 (33.5) | 41 (32.5) | 59 (33.3) |
| Median size, cm | 3.5 (2.5–5) | 3.5 (2.5–5.5) | 3.0 (2.2–5.0) | 4.9 (3.4–6.9) |
| Surgical method | ||||
| Partial nephrectomy | 553 (37.3) | 289 (66.7) | 69 (54.8) | 65 (35.7) |
| Radical nephrectomy | 929 (62.7) | 144 (33.3) | 57 (45.2) | 112 (63.3) |
| Pathologic type | ||||
| Clear cell RCC | 1179 (79.6) | 344 (79.5) | 93 (73.8) | 152 (85.9) |
| Papillary RCC | 118 (8.0) | 19 (4.4) | 9 (7.1) | 16 (9.0) |
| Chromophobe RCC | 89 (6.0) | 30 (6.9) | 6 (4.8) | 9 (5.1) |
| Other Malignanta | 96 (6.4) | 40 (9.2) | 18 (14.3) | 0 (0.0) |
| T stage | ||||
| Ⅰ | 1243 (83.9) | 372 (85.9) | 107 (84.9) | 109 (61.6) |
| Ⅱ | 105 (7.1) | 35 (8.1) | 10 (8.0) | 20 (11.3) |
| Ⅲ | 134 (9.0) | 26 (6.0) | 9 (7.1) | 48 (27.1) |
| ISUP Gradeb | ||||
| Grade 1 | 88 (6.8) | 53 (14.5) | 7 (6.9) | 3 (1.8) |
| Grade 2 | 989 (76.2) | 245 (67.5) | 84 (82.3) | 80 (47.6) |
| Grade 3 | 203 (15.7) | 59 (16.3) | 6 (5.9) | 72 (42.9) |
| Grade 4 | 17 (1.3) | 6 (1.7) | 5 (4.9) | 13 (7.7) |
| Lymph node involvement | ||||
| Absent | 1463 (98.7) | 429 (99.1) | 125 (99.2) | 174 (98.3) |
| Present | 19 (1.3) | 4 (0.9) | 1 (0.8) | 3 (1.7) |
| Sarcomatoid differentiation | ||||
| Absent | 1463 (98.7) | 426 (98.4) | 124 (98.4) | 168 (94.9) |
| Present | 19 (1.3) | 7 (1.6) | 2 (1.6) | 9 (5.1) |
| Necrosis | ||||
| Absent | 1308 (88.3) | 393 (90.8) | 118 (93.7) | 156 (88.1) |
| Present | 174 (11.7) | 40 (9.2) | 8 (6.3) | 21 (11.9) |
| Perinephric or renal sinus fat invasion | ||||
| Absent | 1364 (92.0) | 409 (94.5) | 115 (91.3) | 129 (72.9) |
| Present | 118 (8.0) | 24 (5.5) | 11 (8.7) | 48 (27.1) |
| Tumor thrombus | ||||
| Absent | 1425 (96.2) | 420 (97.0) | 120 (95.2) | 158 (89.3) |
| Present | 57 (3.8) | 13 (3.0) | 6 (4.8) | 19 (10.7) |
| SSIGN | ||||
| Low risk | 1102 (79.1) | 334 (82.9) | 100 (83.3) | 84 (50.0) |
| Intermediate risk | 245 (17.6) | 56 (13.9) | 17 (14.2) | 70 (41.7) |
| High risk | 46 (3.3) | 13 (3.2) | 3 (2.5) | 14 (8.3) |
| Leibovich’Chromophobe RCC risk groups | ||||
| Group 1 | 81 (91.0) | 28 (93.3) | 5 (83.3) | 7 (77.8) |
| Group 2 | 7 (7.9) | 2 (6.7) | 1 (16.7) | 0 (0.0) |
| Group 3 | 1 (1.1) | 0 (0.0) | 0 (0.0) | 2 (22.2) |
| Imaging appearance | ||||
| Cystic | 922 (62.2) | 209 (48.3) | 106 (84.1) | 80 (45.2) |
| Solid | 560 (37.8) | 224 (51.7) | 20 (15.9) | 97 (54.8) |
a
Other malignant tumors included mucinous tubular and spindle cell carcinoma, tubulocystic RCC, eosinophilic solid and cystic RCC, Xp11 translocation RCC, etc.
b
ISUP grade was evaluated in clear cell RCC and papillary RCC only. RCC, renal cell carcinoma; SSIGN, the Stage, Size, Grade and Necrosis.